Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke

Raquel Rodríguez-González1, Tomás Sobrino1, Manuel Rodríguez-Yáñez1, Mónica Millán2, David Brea1, Elena Miranda3, Octavio Moldes1, Juan Pérez4, David A Lomas5, Rogelio Leira1, Antoni Dávalos2 and José Castillo1*

Abstract

Background: Neuroserpin has shown neuroprotective effects in animal models of cerebral ischemia and has been associated with functional outcome after ischemic stroke. Our aim was to study whether neuroserpin serum levels could be associated to biomarkers of excitotoxicity, inflammation and blood brain barrier disruption.

Methods: We prospectively included 129 patients with ischemic stroke (58.1% male; mean age, 72.4 ± 9.6 years) not treated with tPA within 12 hours (h) of symptoms onset (mean time, 4.7 ± 2.1 h). Poor functional outcome at 3 months was considered as a modified Rankin scale score >2. Serum levels of neuroserpin, Interleukin 6 (IL-6), Intercellular adhesion molecule-1 (ICAM-1), active Matrix metalloproteinase 9 (MMP-9), and cellular fibronectin (cFn) (determined by ELISA) and glutamate (determined by HPLC) were measured on admission, 24 and 72 h. The main variable was considered the decrease of neuroserpin levels within the first 24 h. ROC analysis was used to select the best predictive value for neuroserpin to predict poor functional outcome due to a lack of linearity.

Results: The decrease of neuroserpin levels within the first 24 h was negatively correlated with serum levels at 24 hours of glutamate (r = -0.642), IL-6 (r = -0.678), ICAM-1 (r = -0.345), MMP-9 (r = -0.554) and cFn (r = -0.703) (all P < 0.0001). In the multivariate analysis, serum levels of glutamate (OR, 1.04; CI95%, 1.01-1.06, p = 0.001); IL-6 (OR, 1.4; CI95%, 1.1-1.7, p = 0.001); and cFn (OR, 1.3; CI95%, 1.1-1.6, p = 0.002) were independently associated with a decrease of neuroserpin levels <70 ng/mL at 24 h after adjusting for confounding factors.

Conclusions: These findings suggest that neuroprotective properties of neuroserpin may be related to the inhibition of excitotoxicity, inflammation, as well as blood brain barrier disruption that occur after acute ischemic stroke.

Background

Several studies have shown that the serin protease inhibitor, neuroserpin, exerts a neuroprotective effect after brain ischemia, probably due to its natural ability to form an inactivating complex with tissue plasminogen activator (tPA). It is also known that tPA is able to promote neuronal injury in the brain parenchyma by enhancing different mechanisms, such as the activation of microglia [1] as well as affecting neuronal N-methyl-D-aspartate (NMDA) receptor-mediated signalling [2]. This leads to an increased release of cytotoxic agents, such as inflammatory mediators, a matrix metalloproteinase-mediated digestion of the extracellular matrix and a glutamate-induced excitotoxicity. The effect of neuroserpin on reducing this tPA-induced damage in the brain has been studied, and both the overexpression of neuroserpin [3] and neuroserpin treatment after cerebral ischemia [4,5] have proved to be effective in reducing the final lesion. Furthermore, an association between neuroserpin serum levels and functional outcome in patients with ischemic stroke has recently been reported [6]. In the present study, we sought to investigate whether neuroserpin serum levels in patients with ischemic stroke could be associated to serum levels of different molecules of
the ischemic cascade. Thus, glutamate was measured as a marker of excitotoxic damage, interleukin-6 (IL-6) and Intercellular Adhesion Molecule-1 (ICAM-1) as markers of inflammatory response, and matrix metalloproteinase 9 (MMP-9) and cellular fibronectin (cFn) as markers of blood brain barrier disruption after ischemic stroke.

**Patients and methods**

**Study population and patients characteristics**

One hundred and ninety patients with a first-ever ischemic stroke of less than 12 hours from symptoms onset, and previously independent for their daily living activities, were prospectively evaluated to be included in the study. Patients with chronic inflammatory diseases (n = 5), severe hepatic (n = 4), renal (n = 2) or hematological diseases (n = 2), cancer (n = 4) or infectious disease in the 15 days prior to inclusion (n = 5) were excluded due to their impact on stroke outcome and possible interference in neuroserpin levels. Sample size was calculated using EPIDAT software http://www.sergas.es/Mos-trarContidos_N3_T01.aspx?IdPaxina=62715 assuming alpha and beta errors of 0.05 and 0.2, respectively.

Likewise, 26 patients who had received thrombolytic treatment were excluded in order to assess the neuroprotective role of neuroserpin without the disturbance of rtPA. Seven patients did not accept to participate and 6 patients were lost during the follow-up, therefore, a total of 129 patients were finally included in the study. This research was carried out in accordance with the Declaration of Helsinki of the World Medical Association (2000) and approved by the Ethics Committee of the participating hospital. Informed consent was obtained from each patient or their relatives after full explanation of the procedures.

**Clinical variables**

All patients were admitted to an acute stroke unit and treated following the European Stroke Organization guidelines [7]. Medical history recording potential vascular risk factors, blood and coagulation tests, 12-lead ECG, chest radiography, and carotid ultrasonography were performed on admission. Stroke subtype was classified according to the TOAST criteria as atherothrombotic (n = 23), cardioembolic (n = 54), lacunar (n = 15), and undetermined (n = 37) [8]. Stroke severity was assessed by a internationally certified neurologist using the National Institute of Health Stroke Scale (NIHSS) on admission, 24 ± 6 hours, 48 ± 6 hours, 72 ± 24 hours, and at 7 ± 1 and 90 ± 7 days. Early neurological deterioration (END) was diagnosed in those patients who worsened 4 or more points on NIHSS score within the first 48 hours. Functional outcome was evaluated at 3 months using the modified Rankin Scale (mRS), considering a score >2 as poor outcome.

**Neuroimaging variables**

CT scans were carried out on admission and between days 4 and 7. Infarct volume was calculated in the second CT by using the formula 0.5 × a × b × c, where a and b are the largest perpendicular diameters, and c is the number of 1-cm thick sections that contain the lesion. All neuroimaging evaluations were made by the same neuroradiologist who had no knowledge of the patients’ clinical and laboratory results.

**Laboratory determinations**

Serum glucose, platelet count and coagulation tests were assessed in a central laboratory. Blood samples, drawn from all patients on admission, at 24 ± 6 and 72 ± 24 hours, were collected in glass chemistry test tubes, centrifuged at 3000 xg for 10 minutes, and serum immediately frozen and stored at −80°C until analysis. Glutamate levels, as a biomarker of excitotoxicity, were determined by HPLC, using the Waters Pico Tag® Chemistry Package for HPLC amino acids analysis. IL-6 and ICAM-1, as indexes of inflammatory response, were determined by IMMULITE 1000 System (Siemens) and a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit from Bender Medsystems, respectively. Finally, as blood brain barrier disruption markers, active MMP-9 and cFn were determined using GE Healthcare and Biohit Plc ELISA kits, respectively. For neuroserpin quantification, a sandwich ELISA was performed as described previously [6,9,10]. Each sample was assayed in duplicate and intra-assay coefficients of variation sample values were always <15%. Clinical investigators were unaware of the laboratory results until the end of the study, once the database was closed. The absolute difference between basal and 24 hours neuroserpin levels was defined as neuroserpin decrease. All determinations were carried out in a laboratory blind to the clinical outcome and neuroimaging findings.

**Endpoints**

The primary endpoint was the decrease of neuroserpin levels at 24 hours.

**Statistical analysis**

For continuous variables, we tested if data presented a Normal distribution using the Kolgomorov-Smirnov test. Parametric tests were used if they followed a Normal distribution and non-parametric tests if they did not. Mann-Whitney test was used for continuous variables with non-Normal distribution, Student’s t test for continuous variables with Normal distribution and Chi-square test for proportions between patients. In addition Spearman analysis was used for bivariate correlations with non-Normal distribution. Results are expressed as percentages for categorical variables and as mean (SD) or median.
Results
A total of 129 patients (58.1% male; mean age 72.4 ± 9.6 years) who did not receive thrombolytic treatment were prospectively included in the study within 12 hours of symptoms onset (mean time 4.7 ± 2.1 hours). The NIHSS score on admission was 9 [4,14] . Neuroserpin levels on admission were significantly greater [148.4 ± 37.7 ng/mL] than at 24 hours [79.1 ± 52.3 ng/mL] or at 72 hours [80.9 ± 60.5 ng/mL] (all p < 0.0001). No differences in neuroserpin levels between 24 and 72 hours were found. Median neuroserpin decrease within the first 24 hours was 69.4 ± 51.5 ng/mL.

A decrease in neuroserpin levels <70 ng/mL within the first 24 hours predicted the probability of poor outcome (area under curve 0.921, P < 0.0001) with the highest sensitivity (84%) and specificity (91%). For this reason, our analysis focused on those molecular markers of brain injury which were positively associated with a decrease in neuroserpin levels <70 ng/mL at 24 hours.

Neuroserpin and brain injury biomarkers
We evaluated the relationship between neuroserpin levels and brain injury biomarkers on admission as well as between neuroserpin decrease within the first 24 hours and biomarkers serum levels at 24 hours from stroke onset. We did not find a significant correlation between neuroserpin serum levels on admission and glutamate (r = -0.138, p = 0.133), IL-6 (r = -0.062, p = 0.485), ICAM-1 (r = 0.004, p = 0.964), active MMP-9 (r = 0.143, p = 0.224) or cFn (r = -0.139, p = 0.117). However, the decrease of neuroserpin levels within the first 24 h was negatively correlated with serum levels of brain injury biomarkers at 24 hours: glutamate (r = -0.642), IL-6 (r = -0.678), ICAM-1 (r = -0.345), active MMP-9 (r = -0.554), cFn (r = -0.703), (all P < 0.0001) (Figure 1).

Our analysis showed that patients with a decrease of neuroserpin levels within the first 24 hours < 70 ng/mL presented greater serum levels of glutamate, IL-6, ICAM-1, active MMP-9 and cFn at 24 hours (Table 1). In the multivariate analysis, serum levels of glutamate (OR, 1.04; CI 95%, 1.01-1.06, p = 0.001), IL-6 (OR, 1.4; CI 95%, 1.1 - 1.7, p = 0.001) and cFn (OR, 1.3; CI 95%, 1.1 - 1.6, p = 0.002) were independently associated with a decrease of neuroserpin levels < 70 ng/mL after adjustment for age, sex, previous stroke, lesion volume, glucose levels and baseline stroke severity (Table 2).

Discussion
Neuroserpin has extensively shown neuroprotective activity after brain ischemia in experimental models [3-5]. In addition, an association between neuroserpin levels and acute ischemic stroke outcome has recently been reported [6]. However, the mechanisms that are involved in neuroserpin-mediated neuroprotection remain to be well characterized. In order to investigate this, the present study has explored the association between neuroserpin serum levels and established biomarkers of different mechanisms of brain injury which take place after acute ischemic stroke.

The implication of the selected biomarkers in different pathophysiological mechanisms that are triggered by ischemic stroke as well as their clinical value, have been extensively investigated and validated in previous studies carried out by our group as well as by others [10-20]. Hence, glutamate was selected as a biomarker of excitotoxic damage, ICAM-1 and IL-6 as inflammatory biomarkers, and MMP-9 as well as cFn as blood brain barrier disruption biomarkers. We did not find any significant statistical relationship between serum levels of neuroserpin and the selected biomarkers at baseline. However, a negative correlation was found between serum levels of all the biomarkers at 24 hours and neuroserpin decrease within the first 24 hours after stroke onset. Using ROC analysis, we had established a 70 ng/mL cut-off value for the decrease of neuroserpin serum levels within the first 24 hours to predict poor outcome. The results of the present study show a significant association between neuroserpin decrease < 70 ng/mL and serum levels of brain injury biomarkers at 24 hours, which remained independent for glutamate, IL-6 and cFn after adjusting for confounding factors.

Neuroserpin displays a neuroprotective effect in rodent models of cerebral ischemia [3-5] by inhibiting extravascular deleterious effects of tPA in the brain parenchyma. Due to the fact that patients treated with tPA were excluded in our study, neuroserpin would presumably be acting on endogenous tPA, whose expression increases after brain ischemia [4,21].

It has been demonstrated that tPA exacerbates glutamate-mediated excitotoxicity by its interaction with NMDA receptor [22,23] and also that neuroserpin is able to protect neurons from NMDA-induced neuronal
death both in vitro and in vivo [24], probably by limiting this deleterious tPA-mediated effect on glutamatergic signalling. Our results show a significant relationship between a greater neuroserpin decrease in serum within the first 24 h after stroke onset and lower glutamate serum levels at 24 hours. This result seems to be in accordance with experimental studies, suggesting that neuroserpin might affect glutamate-mediated excitotoxic response after ischemic stroke.

We have also found significant relationships between a greater neuroserpin decrease within the first 24 hours from stroke onset and lower levels of the inflammatory biomarkers ICAM-1 and IL-6 at 24 hours. Previous studies by our group have reported associations between serum levels of these inflammatory markers and clinical features such as early neurological deterioration, greater final infarct volume and cerebral edema [14,25]. It is known that tPA, whose expression increases after brain ischemia, activates microglial cells which produce inflammatory molecules that promote neuronal damage [26,27]. In addition, some of these molecules, like tumour necrosis factor alpha (TNF-α) or interleukin-1 beta (IL-1β) strongly up-regulate the expression of adhesion molecules such as ICAM-1 [28], thus contributing to the extension of the lesion. Likewise, the extracellular matrix substrate fibronectin is able to promote microglial activation [29-31].

It has also been proposed that neuroserpin could reduce microglial activation after ischemic stroke due to its ability to form tPA-inactivating complexes in the brain parenchyma [3]. Because neuroserpin serum levels within the first 24 hours are associated with a lower level of the inflammatory biomarkers ICAM-1 and IL-6 at 24 hours, we hypothesize that those patients who show more severe clinical outcome might require more neuroserpin in the brain parenchyma to inactivate tPA, and this could lead to lower neuroserpin levels in serum. Neuroserpin, via complex formation with tPA, could limit microglial activation, therefore the production of inflammatory mediators would be reduced, as reflected by the decreased serum levels observed.

Likewise, after ischemia, an increase in neuroserpin contributes to preserving the integrity of the basement membrane [4] and decreases blood brain barrier leakage, reducing ischemic lesion [5]. MMP-9 is an endopeptidase which mediates extracellular matrix degradation, and glycoprotein fibronectin is one of its substrates [32]. There is abundant evidence indicating that increased MMP-9 expression after ischemia significantly contributes to basal lamina degradation, thus leading to hemorrhagic
transformation of ischemic stroke [18,33-36]. It has also been proved that tPA enhances MMP-9 expression in vitro and in vivo [37,38]. Furthermore, tPA-treated patients show increased plasma levels of MMP-9 [39]. Recent results from our group have also shown a negative correlation between neuroserpin decrease within the first 24 hours and MMP-9 levels at 24 hours in patients treated with tPA [6], which is in line with the results of the present manuscript, where a greater decrease in neuroserpin serum levels within the first 24 hours was correlated with lower serum levels of MMP-9 at 24 hours. Accordingly, we postulate that greater expression of neuroserpin in the brain parenchyma could contribute to stronger downregulation of tPA activity, therefore, reducing tPA-induced MMP-9 expression.

Conclusions

In conclusion, we have found a negative correlation between the decrease in neuroserpin serum levels within the first 24 hours and levels of molecular markers of brain damage at 24 hours after ischemic stroke. We suggest that neuroprotective properties of neuroserpin might be related to the inhibition of tPA-mediated mechanisms of excitotoxicity, inflammation, as well as blood brain barrier disruption that occur after acute ischemic stroke. This is in line with recent results from

| Table 1 Univariate analysis for neuroserpin decrease |
|------------------------------------------|-------------------|-------------------|---|
| Neuroserpin decrease within first 24 h ≥70 ng/mL n = 70 | Neuroserpin decrease within first 24 h <70 ng/mL n = 59 | p |
| Female, % | 30.0 | 55.9 | 0.003 |
| Age, years | 69.9 ± 10.6 | 75.2 ± 7.5 | 0.004 |
| Time from onset, h | 4.8 ± 2.2 | 4.5 ± 2.1 | 0.816 |
| TOAST | | | |
| - Atherothrombotic, % | 17.1 | 18.6 | 0.051 |
| - Cardioembolic, % | 35.7 | 49.2 | 0.284 |
| - Lacunar, % | 18.6 | 3.4 | 0.371 |
| - Indeterminated, % | 28.6 | 28.8 | 0.0084 |
| History of hypertension, % | 57.1 | 69.5 | 0.103 |
| History of diabetes, % | 22.9 | 28.8 | 0.248 |
| History of dyslipemia, % | 21.4 | 25.4 | 0.371 |
| History of atrial fibrillation, % | 20.0 | 32.2 | 0.0084 |
| Previous stroke, % | 2.9 | 15.3 | 0.013 |
| Systolic BP on admission, mm Hg | 147.9 ± 23.6 | 145.6 ± 18.8 | 0.885 |
| Diastolic BP on admission, mm Hg | 81.3 ± 14.2 | 71.6 ± 12.2 | 0.062 |
| Maximum temperature 24 h (°C) | 36.7 ± 0.4 | 36.7 ± 0.5 | 0.943 |
| Glyceria, mg/dL | 120.4 ± 25.3 | 183.7 ± 87.4 | 0.001 |
| Leukocyte count, 10³/mL | 8.7 ± 2.4 | 9.2 ± 2.8 | 0.427 |
| Fibrinogen, mg/dL | 386.9 ± 105.2 | 428.1 ± 136.2 | 0.090 |
| Early neurological deterioration, % | 2.9 | 25.4 | <0.0001 |
| NIHSS on admission | 5 [3,10] | 14 [10,16] | <0.0001 |
| Infarct volume, mL | 18.2 ± 20.9 | 44.4 ± 36.3 | <0.0001 |

**Molecular markers of brain damage**

| Glutamate 24 h, μM | 67.7 ± 54.4 | 149.9 ± 36.3 | <0.0001 |
| IL-6 24 h, pg/mL | 18.4 ± 3.2 | 29.2 ± 8.1 | <0.0001 |
| ICAM-1 24 h, ng/mL | 344.7 ± 122.5 | 430.2 ± 79.1 | <0.0001 |
| Active MMP-9 24 h, ng/mL | 23.9 ± 8.7 | 32.3 ± 11.1 | <0.0001 |
| cFns 24 h, μg/mL | 7.6 ± 1.9 | 13.1 ± 5.6 | <0.0001 |

Baseline clinical characteristics, stroke subtype, vascular risk factors, biochemical parameters, neuroimaging findings and molecular markers of brain damage in patients with a neuroserpin decrease within the first 24 hours ≥70 ng/mL or <70 ng/mL.

| Table 2 Adjusted OR of neuroserpin decrease levels <70 ng/mL at 24 hours for serum levels of glutamate, IL-6, ICAM-1, active MMP-9 and cFns at 24 hours |
|---------------------------------|-------------------|-------------------|---|
| Glutamate at 24 hours | 1.04 (1.01 to 1.06) | 0.001 |
| IL-6 at 24 hours | 1.4 (1.1 to 1.7) | 0.001 |
| ICAM-1 at 24 hours | 1.0 (0.9 to 1.1) | 0.065 |
| Active MMP-9 at 24 hours | 1.1 (0.9 to 1.3) | 0.095 |
| cFns at 24 hours | 1.3 (1.1 to 1.6) | 0.002 |

Adjusted for sex, age, previous stroke, glucose levels, NIHSS on admission and infarct volume.
our group obtained after investigating neuroserpin effects using an in vitro model of brain ischemia [40].

The information reported here regarding biomarkers might be relevant to evaluate the utility of neuroserpin as a potential treatment for ischemic stroke patients. In this respect, combined thrombolytic and neuroprotective therapy continues to be one of the most interesting approaches for ischemic stroke. This and future studies could contribute to better molecular characterization of the deleterious consequences of thrombolytic therapy, and lead to the development of effective strategies to reduce them.

Acknowledgements
This project has been partially supported by grants from the Spanish Ministry of Science and Innovation CIT-090100-2007-42, PI081472 and (Instituto de Salud Carlos III) RETICS-RD06/0026; Xunta de Galicia (Consellería de Innovación, Industria e Comercio: PGIDIT06PXIB918316PR; and the Consellería de Educación e Ordenación Universitaria: Axudas para a Consolidación e Estructuración de Unidades de Investigación Competitivas. Expediente: 80/2006).

Author details
1Clinical Neuroscience Research Laboratory, Department of Neurology, Hospital Clínico Universitario, University of Santiago de Compostela, Santiago de Compostela, Spain. 2Department of Neurosciences, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain. 3University of Cambridge, Cambridge Institute for Medical Research, Cambridge, UK. 4Departamento de Biología Celular, Genética y Fisiología, Universidad de Málaga, Facultad de Ciencias, Campus de Teatinos, Málaga, Spain.

Authors’ contributions
RRG, TS, RL, AD, JC have conceived and designed the research; analyzed and interpreted the data; performed statistical analysis, handled funding and lead to the development of effective strategies to reduce them.

Competing interests
The authors declare that they have no competing interests.

Received: 1 December 2010 Accepted: 11 May 2011 Published: 11 May 2011

References
1. Rogove AD, Siao C, Heyt B, Strickland S, Tisaka SE: Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999, 112:4007-4016.
2. Melchor JP, Strickland S: Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005, 93:655-660.
3. Cnelli P, Madari R, Tsuzuki N, Vallet P, Arras M, Zhao CH, Osterwalder T, Rulicke T, Sonderegger P: Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001, 18:443-457.
4. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, Lawrence DA: Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000, 96:569-576.
5. Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Amego P, Coleman TA, Lawrence DA, Chopp M: Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002, 106:740-745.
6. Rodríguez-González R, Millán M, Sobrino T, Miranda E, Brea D, Pérez de la Ossa N, Blanco M, Pérez J, Dorado L, Castellanos M, Lomas DA, Moro MA, Dávahos A, Castilho J: The natural tissue plasminogen activator inhibitor, neuroserpin and acute ischemic stroke outcome. Thromb Haemost 2011, 105:421-429.
7. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008, 25:457-507.
8. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke 1993, 24:35-41.
9. Miranda E, MacLeod I, Davies MJ, Perez J, Romisch K, Crowther DC, Lomas DA: The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 2008, 17:1527-1539.
10. Miranda E, Romisch K, Lomas DA: Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 2004, 279:28283-28291.
11. Castillo J, Dávahos A, Naveiro J, Noya M: Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke 1996, 27:1060-1065.
12. Castillo J, Dávahos A, Noya M: Progression of ischemic stroke and excitotoxic aminoacids. Lancet 1997, 349:79-83.
13. Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Eikhom S, Tarkowski A: Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997, 110:492-499.
14. Vilà N, Castillo J, Dávahos A, Chamorro A: Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31:2325-2329.
15. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabin J: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
16. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávahos A: Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004, 35:1671-1676.
17. Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, Leira R, Lizasoain I, Castillo J, Dávahos A: The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005, 36:1921-1926.
18. Castellanos M, Sobrino T, Millán M, García M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Dávahos A: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: A multicenter confirmatory study. Stroke 2007, 38:1852-1859.
19. Castellanos M, Serena J: Applicability of biomarkers in ischemic stroke. Cerebrovasc Dis 2007, 24(Suppl 1):17-19.
20. Castellanos M, Castillo J, Dávahos A: Laboratory studies in the investigation of stroke. Handb Clin Neurol 2008, 94:1081-1095.
21. Zhao G, Reynolds JN, Flavin MP: Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia. Neuroreport 2003, 14:1689-1692.
22. Nicole O, Docagne F, Ali C, Margail I, Carmelet P, MacKenzie ET, Vivien D, Buisson A: The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001, 7:59-64.
23. Fernández-Mondeal M, Lopez-Atalaya JP, Benchenane K, Cacquevel M, Dulín F, Le Caer JP, Rossier J, Jarage AC, Mackenzie ET, Colloch N, Ali C, Vivien D: Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of n-methyl-d-aspartate receptor signaling. J Biol Chem 2004, 279:50850-50856.
24. Lebeerier N, Liot G, Lopez-Atalaya JP, Oreset C, Fernandez-Mondeal M, Sonderegger P, Ali C, Vivien D: The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo. Mol Cell Neurosci 2005, 30:552-558.
25. Castellanos M, Castillo J, Garcia MM, Leira R, Serena J, Chamorro A, Dávahos A: Inflammation-mediated damage in progressing lacunar infarctions: A potential therapeutic target. Stroke 2003, 33:982-987.
26. Siao CJ, Fernandez SR, Tsirka SE: Cell type-specific roles for tissue plasminogen activator released by neurons or microglia after excitotoxic injury. J Neurosci 2003, 23:3234-3242.

27. Flavin MP, Zhao G, Ho LT: Microglial tissue plasminogen activator (tpa) triggers neuronal apoptosis in vitro. Glia 2000, 29:347-354.

28. Meager A: Cytokine regulation of cellular adhesion molecule expression in inflammation. Cytokine Growth Factor Rev 1999, 10:27-39.

29. Milner R, Campbell IL: The extracellular matrix and cytokines regulate microglial integrin expression and activation. J Immunol 2003, 170:3850-3858.

30. del Zoppo GJ, Milner R, Mabuchi T, Hung S, Wang X, Berg GI, Koziol JA: Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007, 38:646-651.

31. Summers L, Kielly C, Pinteaux E: Adhesion to fibronectin regulates interleukin-1 beta expression in microglial cells. Mol Cell Neurosci 2009, 41:148-155.

32. Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase b: A tuner and amplifier of immune functions. Trends Immunol 2001, 22:571-579.

33. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR: Increased gelatinase a (mmp-2) and gelatinase b (mmp-9) activities in human brain after focal ischemia. Neurosci Lett 1997, 238:53-56.

34. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ: Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19:624-633.

35. Romanic AM, White RF, Afreigh AJ, Ohlstein EH, Barone FC: Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998, 29:1020-1030.

36. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, Davalos A: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34:40-46.

37. Wang X, Lee SR, Arai K, Tsuji K, Rebeck GW, Lo EH: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003, 9:1313-1317.

38. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH: Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36:1954-1959.

39. Ning M, Furie KL, Koroshetz WJ, Lee H, Barron M, Lederer M, Wang X, Zhu N, Sorensen AG, Lo EH, Kelly PJ: Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology 2006, 66:1550-1555.

40. Rodríguez-González R, Agulla J, Sobrino T, Castillo J: Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA. Neurochem Int 2011, 58:337-343.

Cite this article as: Rodríguez-González et al.: Association between neuroserpin and molecular markers of brain damage in patients with acute ischemic stroke. Journal of Translational Medicine 2011 9:58.